Emergent Biosolutions (NYSE:EBS) Price Target Cut to $12.00 by Analysts at HC Wainwright

Emergent Biosolutions (NYSE:EBS) had its target price reduced by HC Wainwright from $15.00 to $12.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

EBS has been the subject of several other reports. Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday. Weiss Ratings lowered shares of Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Emergent Biosolutions currently has a consensus rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Stock Performance

EBS opened at $8.37 on Monday. The firm has a market cap of $439.59 million, a PE ratio of 9.96 and a beta of 2.41. The company has a quick ratio of 2.41, a current ratio of 5.01 and a debt-to-equity ratio of 1.09. The business has a fifty day simple moving average of $11.21 and a 200-day simple moving average of $10.40. Emergent Biosolutions has a fifty-two week low of $4.02 and a fifty-two week high of $14.06.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.54). The firm had revenue of $148.70 million during the quarter, compared to analysts’ expectations of $217.50 million. Emergent Biosolutions had a return on equity of 15.86% and a net margin of 7.08%. As a group, equities analysts predict that Emergent Biosolutions will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Emergent Biosolutions

A number of institutional investors have recently bought and sold shares of EBS. State Street Corp boosted its holdings in Emergent Biosolutions by 10.2% during the fourth quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock valued at $33,327,000 after purchasing an additional 250,616 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after buying an additional 1,020,582 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Emergent Biosolutions by 3.9% during the 3rd quarter. American Century Companies Inc. now owns 2,382,378 shares of the biopharmaceutical company’s stock worth $21,013,000 after buying an additional 90,216 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Emergent Biosolutions by 5.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,252,605 shares of the biopharmaceutical company’s stock worth $27,841,000 after buying an additional 112,265 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Emergent Biosolutions by 17.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock valued at $20,010,000 after buying an additional 237,153 shares in the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.